On the public citation graph
Discovery of Di- and Trihaloacetamides as Covalent SARS-CoV-2 Main Protease Inhibitors with High Target Specificity
0 signed · 192 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1002/cbic.202000047openalex-snapshot
Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019‐nCoV
inferredcites →https://doi.org/10.1002/cmdc.202000223openalex-snapshot
Drug Development and Medicinal Chemistry Efforts toward SARS‐Coronavirus and Covid‐19 Therapeutics
inferredcites →https://doi.org/10.1002/cmdc.202000924openalex-snapshot
A Quick Route to Multiple Highly Potent SARS‐CoV‐2 Main Protease Inhibitors**
inferredcites →https://doi.org/10.1002/cmdc.202100456openalex-snapshot
MPI8 is Potent against SARS‐CoV‐2 by Inhibiting Dually and Selectively the SARS‐CoV‐2 Main Protease and the Host Cathepsin L**
inferredcites →https://doi.org/10.1016/j.apsb.2015.08.001openalex-snapshot
Cysteine proteases as therapeutic targets: does selectivity matter? A systematic review of calpain and cathepsin inhibitors
inferredcites →https://doi.org/10.1016/j.bbrc.2021.03.096openalex-snapshot
ALG-097111, a potent and selective SARS-CoV-2 3-chymotrypsin-like cysteine protease inhibitor exhibits in vivo efficacy in a Syrian Hamster model
inferredcites →https://doi.org/10.1016/j.bmc.2020.115865openalex-snapshot
The advantages of describing covalent inhibitor in vitro potencies by IC50 at a fixed time point. IC50 determination of covalent inhibitors provides meaningful data to medicinal chemistry for SAR optimization
inferredcites →https://doi.org/10.1016/j.cell.2020.02.052openalex-snapshot
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
inferredcites →https://doi.org/10.1016/j.celrep.2020.107863openalex-snapshot
Critical Role of Type III Interferon in Controlling SARS-CoV-2 Infection in Human Intestinal Epithelial Cells
inferredcites →https://doi.org/10.1021/acs.jmedchem.0c01063openalex-snapshot
Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19
inferredcites →https://doi.org/10.1021/acs.jmedchem.1c00509openalex-snapshot
Expedited Approach toward the Rational Design of Noncovalent SARS-CoV-2 Main Protease Inhibitors
inferredcites →https://doi.org/10.1021/acs.jmedchem.9b00683openalex-snapshot
Can Cysteine Protease Cross-Class Inhibitors Achieve Selectivity?
inferredcites →https://doi.org/10.1021/acsinfecdis.0c00761openalex-snapshot
Boceprevir, Calpain Inhibitors II and XII, and GC-376 Have Broad-Spectrum Antiviral Activity against Coronaviruses
inferredcites →https://doi.org/10.1021/acsinfecdis.0c00815openalex-snapshot
Challenges for Targeting SARS-CoV-2 Proteases as a Therapeutic Strategy for COVID-19
inferredcites →https://doi.org/10.1021/acsptsci.1c00099openalex-snapshot
Rational Design of Hybrid SARS-CoV-2 Main Protease Inhibitors Guided by the Superimposed Cocrystal Structures with the Peptidomimetic Inhibitors GC-376, Telaprevir, and Boceprevir
inferredcites →https://doi.org/10.1021/bi036022qopenalex-snapshot
3C-like Proteinase from SARS Coronavirus Catalyzes Substrate Hydrolysis by a General Base Mechanism
inferredcites →https://doi.org/10.1021/ja0637649openalex-snapshot
Organic Azide Inhibitors of Cysteine Proteases
inferredcites →https://doi.org/10.1021/jacs.0c10770openalex-snapshot
Proton-Coupled Conformational Activation of SARS Coronavirus Main Proteases and Opportunity for Designing Small-Molecule Broad-Spectrum Targeted Covalent Inhibitors
inferredcites →https://doi.org/10.1021/jm301580nopenalex-snapshot
Discovery, Synthesis, And Structure-Based Optimization of a Series of N-(tert-Butyl)-2-(N-arylamido)-2-(pyridin-3-yl) Acetamides (ML188) as Potent Noncovalent Small Molecule Inhibitors of the Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) 3CL Protease
inferredcites →https://doi.org/10.1021/ol800575zopenalex-snapshot
Solid-Phase Synthesis of Azidomethylene Inhibitors Targeting Cysteine Proteases
inferredcites →https://doi.org/10.1038/s41422-020-0356-zopenalex-snapshot
Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease
inferredcites →https://doi.org/10.1038/s41467-020-18096-2openalex-snapshot
Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication
inferredcites →https://doi.org/10.1038/s41467-020-18709-wopenalex-snapshot
Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease
inferredcites →https://doi.org/10.1038/s41467-021-26239-2openalex-snapshot
Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19
inferredcites →https://doi.org/10.1038/s41564-020-00835-2openalex-snapshot
Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets
inferredcites →https://doi.org/10.1038/s41579-021-00573-0openalex-snapshot
SARS-CoV-2 variants, spike mutations and immune escape
inferredcites →https://doi.org/10.1038/s41598-021-89013-wopenalex-snapshot
Efficacy of GC-376 against SARS-CoV-2 virus infection in the K18 hACE2 transgenic mouse model
inferredcites →https://doi.org/10.1039/c8cc01485jopenalex-snapshot
Cysteine-reactive probes and their use in chemical proteomics
inferredcites →https://doi.org/10.1039/c9cs00720bopenalex-snapshot
Advances in covalent kinase inhibitors
inferredcites →https://doi.org/10.1073/pnas.2003138117openalex-snapshot
Cell entry mechanisms of SARS-CoV-2
inferredcites →https://doi.org/10.1073/pnas.2101555118openalex-snapshot
Postinfection treatment with a protease inhibitor increases survival of mice with a fatal SARS-CoV-2 infection
inferredcites →https://doi.org/10.1126/sciadv.abe0751openalex-snapshot
Structure and inhibition of the SARS-CoV-2 main protease reveal strategy for developing dual inhibitors against M pro and cathepsin L
inferredcites →https://doi.org/10.1126/science.abb4489openalex-snapshot
Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease
inferredcites →https://doi.org/10.1126/science.abf1611openalex-snapshot
SARS-CoV-2 M pro inhibitors with antiviral activity in a transgenic mouse model
inferredcites →https://doi.org/10.1126/science.abf7945openalex-snapshot
X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease
inferredcites →https://doi.org/10.1126/science.abg5827openalex-snapshot
Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2
inferredcites →https://doi.org/10.1126/science.abl4784openalex-snapshot
An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19
inferredcites →https://doi.org/10.1126/scitranslmed.abc5332openalex-snapshot
3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV–infected mice
inferredcites →https://doi.org/10.1128/jvi.00239-10openalex-snapshot
TMPRSS2 and TMPRSS4 Facilitate Trypsin-Independent Spread of Influenza Virus in Caco-2 Cells
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.1002/ange.202309657openalex-snapshot
The S1′–S3′ Pocket of the SARS‐CoV‐2 Main Protease Is Critical for Substrate Selectivity and Can Be Targeted with Covalent Inhibitors
inferred← citeshttps://doi.org/10.1002/anie.202309657openalex-snapshot
The S1′–S3′ Pocket of the SARS‐CoV‐2 Main Protease Is Critical for Substrate Selectivity and Can Be Targeted with Covalent Inhibitors
inferred← citeshttps://doi.org/10.1002/ardp.70175openalex-snapshot
Sequential Optimization Approach Toward an Azapeptide‐Based SARS‐CoV‐2 Main Protease Inhibitor
inferred← citeshttps://doi.org/10.1002/cbdv.202300957openalex-snapshot
Discovery of SARS‐CoV‐2 Inhibitors Featuring Novel Histidine α‐Nitrile Motif
inferred← citeshttps://doi.org/10.1002/cbdv.202403242openalex-snapshot
Investigation of Pyrrole Analogues Inhibition on Main Protease by Spectroscopic Analysis, Molecular Docking, and Enzyme Activity
inferred← citeshttps://doi.org/10.1002/chem.202300476openalex-snapshot
Development of the Safe and Broad‐Spectrum Aldehyde and Ketoamide Mpro inhibitors Derived from the Constrained α, γ‐AA Peptide Scaffold
inferred← citeshttps://doi.org/10.1002/chem.202303940openalex-snapshot
Protein‐Templated Ugi Reactions versus In‐Situ Ligation Screening: Two Roads to the Identification of SARS‐CoV‐2 Main Protease Inhibitors
inferred← citeshttps://doi.org/10.1002/cmdc.202200440openalex-snapshot
Recent Drug Development and Medicinal Chemistry Approaches for the Treatment of SARS‐CoV‐2 Infection and COVID‐19
inferred← citeshttps://doi.org/10.1002/cmdc.202200635openalex-snapshot
A Critical Study on Acylating and Covalent Reversible Fragment Inhibitors of SARS‐CoV‐2 Main Protease Targeting the S1 Site with Pyridine
inferred← citeshttps://doi.org/10.1002/jmv.28609openalex-snapshot
Sulforaphane is a reversible covalent inhibitor of 3‐chymotrypsin‐like protease of SARS‐CoV‐2
inferred← citeshttps://doi.org/10.1002/ptr.7651openalex-snapshot
Recruitment of chalcone's potential in drug discovery of a nti‐SARS‐CoV ‐2 agents
inferred← citeshttps://doi.org/10.1007/s00044-022-02903-0openalex-snapshot
Invalidation of dieckol and 1,2,3,4,6-pentagalloylglucose (PGG) as SARS-CoV-2 main protease inhibitors and the discovery of PGG as a papain-like protease inhibitor
inferred← citeshttps://doi.org/10.1007/s10822-024-00554-4openalex-snapshot
Benchmarking ANI potentials as a rescoring function and screening FDA drugs for SARS-CoV-2 Mpro
inferred← citeshttps://doi.org/10.1007/s13659-025-00523-wopenalex-snapshot
Exploring anti-SARS-CoV-2 natural products: dual-viral target inhibition by delphinidin and the anti-coronaviral efficacy of deapio platycodin D
inferred← citeshttps://doi.org/10.1016/b978-0-443-36518-8.00023-0openalex-snapshot
Targeting 3CLpro for broad-spectrum antiviral therapy: Structural insights, inhibitor development, and the future of PROTACs
inferred← citeshttps://doi.org/10.1016/j.antiviral.2024.105841openalex-snapshot
Methyl rosmarinate is an allosteric inhibitor of SARS-CoV-2 3 CL protease as a potential candidate against SARS-cov-2 infection
inferred← citeshttps://doi.org/10.1016/j.antiviral.2024.105874openalex-snapshot
Azapeptides with unique covalent warheads as SARS-CoV-2 main protease inhibitors
inferred← citeshttps://doi.org/10.1016/j.apsb.2024.04.011openalex-snapshot
Discovery and characterization of novel potent non-covalent small molecule inhibitors targeting papain-like protease from SARS-CoV-2
inferred← citeshttps://doi.org/10.1016/j.apsb.2025.06.029openalex-snapshot
Yeast-two-hybrid based high-throughput screening to discover SARS-CoV-2 fusion inhibitors by targeting the HR1/HR2 interaction
inferred← citeshttps://doi.org/10.1016/j.bcp.2026.117791openalex-snapshot
From 2020 to 2025: Comprehensive review Decoding novel structural inhibitors for Mpro of SARS-CoV-2
inferred← citeshttps://doi.org/10.1016/j.bioorg.2024.107380openalex-snapshot
Non-peptidic inhibitors targeting SARS-CoV-2 main protease: A review
inferred← citeshttps://doi.org/10.1016/j.bioorg.2026.109490openalex-snapshot
Design, synthesis, and antifungal evaluation of Prp8 Intein-targeting small molecule inhibitors against Cryptococcus neoformans
inferred← citeshttps://doi.org/10.1016/j.bioorg.2026.110402openalex-snapshot
Design, synthesis, and structural characterization of covalent tetrahydroquinoline-based inhibitors of coronavirus 3CLpro
inferred← citeshttps://doi.org/10.1016/j.bmcl.2022.128732openalex-snapshot
Identification of Aloe-derived natural products as prospective lead scaffolds for SARS-CoV-2 main protease (Mpro) inhibitors
inferred← citeshttps://doi.org/10.1016/j.bmcl.2022.128867openalex-snapshot
Discovery of 2-thiobenzimidazoles as noncovalent inhibitors of SARS-CoV-2 main protease
inferred← citeshttps://doi.org/10.1016/j.bmcl.2023.129407openalex-snapshot
Discovery of benzodiazepine derivatives as a new class of covalent inhibitors of SARS-CoV–2 main protease
inferred← citeshttps://doi.org/10.1016/j.drudis.2023.103579openalex-snapshot
COVID-19 therapeutics: Small-molecule drug development targeting SARS-CoV-2 main protease
inferred← citeshttps://doi.org/10.1016/j.drudis.2023.103799openalex-snapshot
The expanding repertoire of covalent warheads for drug discovery
inferred← citeshttps://doi.org/10.1016/j.ejmech.2022.114570openalex-snapshot
A multi-pronged evaluation of aldehyde-based tripeptidyl main protease inhibitors as SARS-CoV-2 antivirals
inferred← citeshttps://doi.org/10.1016/j.ejmech.2022.114596openalex-snapshot
A systematic exploration of boceprevir-based main protease inhibitors as SARS-CoV-2 antivirals
inferred← citeshttps://doi.org/10.1016/j.ejmech.2022.114803openalex-snapshot
Discovery of novel SARS-CoV-2 3CL protease covalent inhibitors using deep learning-based screen
inferred← citeshttps://doi.org/10.1016/j.ejmech.2023.115129openalex-snapshot
Discovery, synthesis and mechanism study of 2,3,5-substituted [1,2,4]-thiadiazoles as covalent inhibitors targeting 3C-Like protease of SARS-CoV-2
inferred← citeshttps://doi.org/10.1016/j.ejmech.2023.115376openalex-snapshot
Structure-guided design of direct-acting antivirals that exploit the gem-dimethyl effect and potently inhibit 3CL proteases of severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2) and middle east respiratory syndrome coronavirus (MERS-CoV)
inferred← citeshttps://doi.org/10.1016/j.ejmech.2023.115491openalex-snapshot
The research progress of SARS-CoV-2 main protease inhibitors from 2020 to 2022
inferred← citeshttps://doi.org/10.1016/j.ejmech.2023.115503openalex-snapshot
Bench-to-bedside: Innovation of small molecule anti-SARS-CoV-2 drugs in China
inferred← citeshttps://doi.org/10.1016/j.ejmech.2023.115667openalex-snapshot
Exploring diverse reactive warheads for the design of SARS-CoV-2 main protease inhibitors
inferred← citeshttps://doi.org/10.1016/j.ejmech.2023.115721openalex-snapshot
Discovery of highly potent covalent SARS-CoV-2 3CLpro inhibitors bearing 2-sulfoxyl-1,3,4-oxadiazole scaffold for combating COVID-19
inferred← citeshttps://doi.org/10.1016/j.ejmech.2023.115772openalex-snapshot
Structure and function of SARS-CoV and SARS-CoV-2 main proteases and their inhibition: A comprehensive review
inferred← citeshttps://doi.org/10.1016/j.ejmech.2023.115979openalex-snapshot
Development of de-novo coronavirus 3-chymotrypsin-like protease (3CLpro) inhibitors since COVID-19 outbreak: A strategy to tackle challenges of persistent virus infection
inferred← citeshttps://doi.org/10.1016/j.ejmech.2024.116704openalex-snapshot
Covalent small-molecule inhibitors of SARS-CoV-2 Mpro: Insights into their design, classification, biological activity, and binding interactions
inferred← citeshttps://doi.org/10.1016/j.ejmech.2024.116707openalex-snapshot
N-acylbenzimidazoles as selective Acylators of the catalytic cystein of the coronavirus 3CL protease
inferred← citeshttps://doi.org/10.1016/j.ejmech.2024.116788openalex-snapshot
How many organic small molecules might be used to treat COVID-19? From natural products to synthetic agents
inferred← citeshttps://doi.org/10.1016/j.ejmech.2024.116963openalex-snapshot
Naphthalen-1-ylethanamine–containing small molecule inhibitors of the papain-like protease of SARS-CoV-2
inferred← citeshttps://doi.org/10.1016/j.ejmech.2024.117202openalex-snapshot
Innovative design and potential applications of covalent strategy in drug discovery
inferred← citeshttps://doi.org/10.1016/j.ejmech.2025.117603openalex-snapshot
Silaproline-bearing nirmatrelvir derivatives are potent inhibitors of the SARS-CoV-2 main protease highlighting the value of silicon-derivatives in structure-activity-relationship studies
inferred← citeshttps://doi.org/10.1016/j.ejmech.2026.119264openalex-snapshot
Cysteine-targeting covalent inhibition: Recent trends and emerging strategies
inferred← citeshttps://doi.org/10.1016/j.ijbiomac.2023.128623openalex-snapshot
Danshensu inhibits SARS-CoV-2 by targeting its main protease as a specific covalent inhibitor and discovery of bifunctional compounds eliciting antiviral and anti-inflammatory activity
inferred← citeshttps://doi.org/10.1016/j.ijbiomac.2024.133706openalex-snapshot
Crystal structures of coronaviral main proteases in complex with the non-covalent inhibitor X77
inferred← citeshttps://doi.org/10.1016/j.isci.2022.105365openalex-snapshot
Potent and biostable inhibitors of the main protease of SARS-CoV-2
inferred← citeshttps://doi.org/10.1016/j.jmgm.2025.109151openalex-snapshot
Identification of novel non-covalent Mpro inhibitors against SARS-CoV-2 by the computational and experimental approaches
inferred← citeshttps://doi.org/10.1016/j.molstruc.2026.145714openalex-snapshot
N-(Benzofuran-3-ylmethyl)isatin derivatives as potential SARS-CoV-2 main protease inhibitors: Synthesis, biological evaluation, kinetic analysis, and molecular modeling insights
inferred← citeshttps://doi.org/10.1016/j.rineng.2026.111662openalex-snapshot
Investigating the effect of variable electric-field amplitude and frequency on the interaction of water/silver nanofluid with the SARS-CoV-2 main protease: a molecular dynamics study
inferred← citeshttps://doi.org/10.1016/j.virol.2025.110659openalex-snapshot
A rapid and robust luciferase-based reporter system to assess SARS-CoV-2 protease activity
inferred← citeshttps://doi.org/10.1016/j.xcrp.2026.103349openalex-snapshot
Pyridinyl ring defines a noncanonical P1-S1 axis that revamps inhibitor design against coronaviral main proteases
inferred← citeshttps://doi.org/10.1016/j.xpro.2023.102323openalex-snapshot
FlipGFP protease assay for evaluating in vitro inhibitory activity against SARS-CoV-2 Mpro and PLpro
inferred← citeshttps://doi.org/10.1021/acs.accounts.2c00735openalex-snapshot
SARS-CoV-2 Main Protease Drug Design, Assay Development, and Drug Resistance Studies
inferred← citeshttps://doi.org/10.1021/acs.accounts.6c00361openalex-snapshot
SARS-CoV-2 Papain-Like Protease: Drug Design, Assay Development, and Drug Resistance
inferred← citeshttps://doi.org/10.1021/acs.biochem.5c00794openalex-snapshot
Early Kinetic Characterization of SARS-CoV-2 Main Protease Inhibitors: A Review and Guidance for Biochemical Assessments
inferred← citeshttps://doi.org/10.1021/acs.jcim.3c00105openalex-snapshot
Elucidating Atomistic Insight into the Dynamical Responses of the SARS-CoV-2 Main Protease for the Binding of Remdesivir Analogues: Leveraging Molecular Mechanics To Decode the Inhibition Mechanism
inferred← citeshttps://doi.org/10.1021/acs.jcim.5c01238openalex-snapshot
Mechanistic Investigation of Cysteine-Targeted Covalent Inhibition of DJ-1 via MD, QM/MM, and SAPT Computations
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.1c02214openalex-snapshot
Penicillin Derivatives Inhibit the SARS-CoV-2 Main Protease by Reaction with Its Nucleophilic Cysteine
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.2c00303openalex-snapshot
Progress and Challenges in Targeting the SARS-CoV-2 Papain-like Protease
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.2c00404openalex-snapshot
Evolutionary and Structural Insights about Potential SARS-CoV-2 Evasion of Nirmatrelvir
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.2c00954openalex-snapshot
Structure-Based Design of a Dual-Targeted Covalent Inhibitor Against Papain-like and Main Proteases of SARS-CoV-2
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.2c01005openalex-snapshot
Targeting SARS-CoV-2 Main Protease for Treatment of COVID-19: Covalent Inhibitors Structure–Activity Relationship Insights and Evolution Perspectives
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.2c01081openalex-snapshot
Discovery of Chlorofluoroacetamide-Based Covalent Inhibitors for Severe Acute Respiratory Syndrome Coronavirus 2 3CL Protease
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.2c01146openalex-snapshot
Discovery and Crystallographic Studies of Trisubstituted Piperazine Derivatives as Non-Covalent SARS-CoV-2 Main Protease Inhibitors with High Target Specificity and Low Toxicity
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.2c01627openalex-snapshot
Alkyne Derivatives of SARS-CoV-2 Main Protease Inhibitors Including Nirmatrelvir Inhibit by Reacting Covalently with the Nucleophilic Cysteine
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.2c01716openalex-snapshot
Discovery and Crystallographic Studies of Nonpeptidic Piperazine Derivatives as Covalent SARS-CoV-2 Main Protease Inhibitors
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.3c00221openalex-snapshot
A Systematic Survey of Reversibly Covalent Dipeptidyl Inhibitors of the SARS-CoV-2 Main Protease
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.3c00504openalex-snapshot
Discovery of a New-Generation S-Adenosylmethionine-Noncompetitive Covalent Inhibitor Targeting the Lysine Methyltransferase Enhancer of Zeste Homologue 2
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.3c00737openalex-snapshot
Expanding the Chemistry of Dihaloacetamides as Tunable Electrophiles for Reversible Covalent Targeting of Cysteines
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.3c00777openalex-snapshot
Structure–Activity Relationship Studies of SARS-CoV-2 Main Protease Inhibitors Containing 4-Fluorobenzothiazole-2-carbonyl Moieties
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.3c00818openalex-snapshot
Discovery and Mechanism Study of SARS-CoV-2 3C-like Protease Inhibitors with a New Reactive Group
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.3c01825openalex-snapshot
Emerging and Re-emerging Warheads for Targeted Covalent Inhibitors: An Update
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.3c02063openalex-snapshot
Discovery of the First-in-Class RORγ Covalent Inhibitors for Treatment of Castration-Resistant Prostate Cancer
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.4c01872openalex-snapshot
Structure-Based Design of Covalent SARS-CoV-2 Papain-like Protease Inhibitors
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.5c01520openalex-snapshot
Azapeptide-Based SARS-CoV-2 Main Protease Inhibitors: Design, Synthesis, Enzyme Inhibition, Structural Determination, and Antiviral Activity
inferred← citeshttps://doi.org/10.1021/acs.jnatprod.4c00657openalex-snapshot
Discovery of Chalcone Derivatives as Bifunctional Molecules with Anti-SARS-CoV-2 and Anti-inflammatory Activities
inferred← citeshttps://doi.org/10.1021/acsbiomedchemau.6c00072openalex-snapshot
Structure-Based Design of New Nonpeptidic Covalent Mpro Inhibitors against SARS-CoV-2 and Omicron Variants
inferred← citeshttps://doi.org/10.1021/acschembio.2c00695openalex-snapshot
A Novel Y-Shaped, S–O–N–O–S-Bridged Cross-Link between Three Residues C22, C44, and K61 Is Frequently Observed in the SARS-CoV-2 Main Protease
inferred← citeshttps://doi.org/10.1021/acschembio.6c00120openalex-snapshot
A Novel Covalent Inhibitor Fragment for the SARS-CoV-2 Main Protease Identified by Target-Specific Deep Learning
inferred← citeshttps://doi.org/10.1021/acsinfecdis.3c00565openalex-snapshot
Design, Synthesis, X-ray Crystallography, and Biological Activities of Covalent, Non-Peptidic Inhibitors of SARS-CoV-2 Main Protease
inferred← citeshttps://doi.org/10.1021/acsmedchemlett.5c00773openalex-snapshot
Ugi-Tetrazole-Derived α-Aminomethyl Scaffolds Reveal Unexpected Binding Modes in SARS-CoV-2 3CLpro
inferred← citeshttps://doi.org/10.1021/acsmedchemlett.6c00236openalex-snapshot
Nitrile-Based Inhibitors Targeting both SARS-CoV-2 Main Protease and Human Cathepsin L
inferred← citeshttps://doi.org/10.1021/acsomega.4c03023openalex-snapshot
Progress in Research on Inhibitors Targeting SARS-CoV-2 Main Protease (M pro )
inferred← citeshttps://doi.org/10.1021/acsomega.5c05168openalex-snapshot
SARS-CoV-2 Main Protease Inhibitors Containing 5-Substituted Benzothiazole-2-carbonyl Moieties at the P1′ Site and Their Derivatives
inferred← citeshttps://doi.org/10.1021/acsomega.5c05856openalex-snapshot
SARS-CoV-2 Papain-Like Protease Inhibitors Based on Naphthalen-1-ylethanamine and Halogenated Benzene Moieties
inferred← citeshttps://doi.org/10.1021/acsptsci.4c00369openalex-snapshot
Novel Alkynylamide-Based Nonpeptidic Allosteric Inhibitors for SARS-CoV-2 3-Chymotrypsin-like Protease
inferred← citeshttps://doi.org/10.1021/jacs.2c04626openalex-snapshot
Dual Inhibitors of Main Protease (M Pro ) and Cathepsin L as Potent Antivirals against SARS-CoV2
inferred← citeshttps://doi.org/10.1021/jacs.2c08853openalex-snapshot
Sulfamate Acetamides as Self-Immolative Electrophiles for Covalent Ligand-Directed Release Chemistry
inferred← citeshttps://doi.org/10.1021/jacs.4c07920openalex-snapshot
SuFEx Chemistry Enables Covalent Assembly of a 280-kDa 18-Subunit Pore-Forming Complex
inferred← citeshttps://doi.org/10.1021/jacs.6c01119openalex-snapshot
Nicotine-Inspired, De Novo-Designed SARS-CoV-2 Main Protease Inhibitors Reveal Unique Chemistry for Covalently Conjugating Both Cysteine and Histidine Residues in the Catalytic Dyad
inferred← citeshttps://doi.org/10.1021/jacs.6c03429openalex-snapshot
Molecular Glues Recruiting RNF213 As an E3 Ligase for Targeted Protein Degradation: A Minimal Dibromoacetamide Warhead As a Recruitment Ligand
inferred← citeshttps://doi.org/10.1021/jacsau.6c00371openalex-snapshot
High-Throughput Screening Identifies Covalent Inhibitors with Unique Chemistry and Binding Modes for SARS-CoV-2 Main Protease
inferred← citeshttps://doi.org/10.1021/mc-2024-vol59.ch13openalex-snapshot
PEPTIDIC OR NON-PEPTIDIC: EVALUATION OF SMALL-MOLECULE CHEMICAL MATTER IN TARGETING PROTEASES FOR ANTIVIRAL TREATMENT
inferred← citeshttps://doi.org/10.1038/s41392-022-01249-8openalex-snapshot
Small molecules in the treatment of COVID-19
inferred← citeshttps://doi.org/10.1038/s41467-024-55421-5openalex-snapshot
Development of small molecule non-covalent coronavirus 3CL protease inhibitors from DNA-encoded chemical library screening
inferred← citeshttps://doi.org/10.1038/s41467-025-56902-xopenalex-snapshot
Design of quinoline SARS-CoV-2 papain-like protease inhibitors as oral antiviral drug candidates
inferred← citeshttps://doi.org/10.1038/s41467-025-59870-4openalex-snapshot
A novel, covalent broad-spectrum inhibitor targeting human coronavirus Mpro
inferred← citeshttps://doi.org/10.1038/s41467-025-59922-9openalex-snapshot
Identification of naturally occurring drug-resistant mutations of SARS-CoV-2 papain-like protease
inferred← citeshttps://doi.org/10.1038/s41467-026-71436-6openalex-snapshot
Next-generation inhibitors of SARS-CoV-2 Mpro overcome the deficiencies of Paxlovid
inferred← citeshttps://doi.org/10.1038/s41564-022-01119-7openalex-snapshot
An orally available Mpro inhibitor is effective against wild-type SARS-CoV-2 and variants including Omicron
inferred← citeshttps://doi.org/10.1038/s41564-024-01618-9openalex-snapshot
Preclinical evaluation of the SARS-CoV-2 Mpro inhibitor RAY1216 shows improved pharmacokinetics compared with nirmatrelvir
inferred← citeshttps://doi.org/10.1038/s41598-022-18676-wopenalex-snapshot
Evaluation of the anti-SARS-CoV-2 properties of essential oils and aromatic extracts
inferred← citeshttps://doi.org/10.1038/s41598-025-05375-5openalex-snapshot
Identification of potential COVID-19 Mpro inhibitors through covalent drug docking, molecular dynamics simulation, and MMGBSA calculation
inferred← citeshttps://doi.org/10.1038/s42004-022-00758-5openalex-snapshot
A sustainable synthesis of the SARS-CoV-2 Mpro inhibitor nirmatrelvir, the active ingredient in Paxlovid
inferred← citeshttps://doi.org/10.1038/s42004-024-01104-7openalex-snapshot
Peptidyl nitroalkene inhibitors of main protease rationalized by computational and crystallographic investigations as antivirals against SARS-CoV-2
inferred← citeshttps://doi.org/10.1039/bk9781839167669-00104openalex-snapshot
(Photo)affinity Label and Covalent Inhibitor Design
inferred← citeshttps://doi.org/10.1039/d1sc06596copenalex-snapshot
Selective covalent targeting of SARS-CoV-2 main protease by enantiopure chlorofluoroacetamide
inferred← citeshttps://doi.org/10.1039/d2md00216gopenalex-snapshot
Advanced approaches of developing targeted covalent drugs
inferred← citeshttps://doi.org/10.1039/d2md00344aopenalex-snapshot
Advances in research on 3C-like protease (3CL pro ) inhibitors against SARS-CoV-2 since 2020
inferred← citeshttps://doi.org/10.1039/d2sc04147bopenalex-snapshot
Azapeptide activity-based probes for the SARS-CoV-2 main protease enable visualization of inhibition in infected cells
inferred← citeshttps://doi.org/10.1039/d2sc06209gopenalex-snapshot
Two birds one stone: β-fluoropyrrolyl-cysteine S N Ar chemistry enabling functional porphyrin bioconjugation
inferred← citeshttps://doi.org/10.1039/d3md00493gopenalex-snapshot
On the origins of SARS-CoV-2 main protease inhibitors
inferred← citeshttps://doi.org/10.1039/d3qo00611eopenalex-snapshot
Direct benzylic polychlorination of (poly)azines with N -chlorosuccinimide
inferred← citeshttps://doi.org/10.1039/d4an00372aopenalex-snapshot
A SARS-CoV-2 M pro fluorescent sensor for exploring pharmacodynamic substances from traditional Chinese medicine
inferred← citeshttps://doi.org/10.1039/d4ra03965copenalex-snapshot
Artificial intelligence-aiding lab-on-a-chip workforce designed oral [3.1.0] bi and [4.2.0] tricyclic catalytic interceptors inhibiting multiple SARS-CoV-2 protomers assisted by double-shell deep learning
inferred← citeshttps://doi.org/10.1039/d5md00789eopenalex-snapshot
C6-Alkoxy substituted penicillins are potent non-covalently binding inhibitors of the SARS-CoV-2 main protease
inferred← citeshttps://doi.org/10.1039/d6ra06004hopenalex-snapshot
Design and synthesis of 1,3,4-oxadiazole-tethered N -substituted isatin hybrids as SARS-CoV-2 main protease inhibitors: biological evaluation, kinetic investigation, and in silico studies
inferred← citeshttps://doi.org/10.1042/bsr20231395openalex-snapshot
3-chymotrypsin-like protease in SARS-CoV-2
inferred← citeshttps://doi.org/10.1055/a-2519-9876openalex-snapshot
Noncovalent Inhibitors of SARS-CoV-2 Main Protease: A Rescaffolding Attempt
inferred← citeshttps://doi.org/10.1063/5.0123698openalex-snapshot
Polarizable MD and QM/MM investigation of acrylamide-based leads to target the main protease of SARS-CoV-2
inferred← citeshttps://doi.org/10.1080/0889311x.2023.2222275openalex-snapshot
Structural biology of SARS-CoV-1/SARS-CoV-2 main protease
inferred← citeshttps://doi.org/10.1080/14756366.2025.2460045openalex-snapshot
Exploring covalent inhibitors of SARS-CoV-2 main protease: from peptidomimetics to novel scaffolds
inferred← citeshttps://doi.org/10.1080/17568919.2026.2642579openalex-snapshot
Overview of recent strategic advances in antiviral covalent inhibitors
inferred← citeshttps://doi.org/10.1101/2022.04.29.490044openalex-snapshot
A Novel Y-Shaped, S-O-N-O-S-Bridged Crosslink between Three Residues C22, C44, and K61 Is a Redox Switch of the SARS-CoV-2 Main Protease
inferred← citeshttps://doi.org/10.1101/2023.03.09.531862openalex-snapshot
Inhibition mechanism and antiviral activity of an α-ketoamide based SARS-CoV-2 main protease inhibitor
inferred← citeshttps://doi.org/10.1101/2023.04.11.536467openalex-snapshot
An Azapeptide Platform in Conjunction with Covalent Warheads to Uncover High-Potency Inhibitors for SARS-CoV-2 Main Protease
inferred← citeshttps://doi.org/10.1111/cbdd.14425openalex-snapshot
Progress of SARS‐CoV‐2 Main protease peptide‐like inhibitors
inferred← citeshttps://doi.org/10.1128/aac.00562-24openalex-snapshot
Design of novel and highly selective SARS-CoV-2 main protease inhibitors
inferred← citeshttps://doi.org/10.1128/mbio.02878-23openalex-snapshot
Potent 3CLpro inhibitors effective against SARS-CoV-2 and MERS-CoV in animal models by therapeutic treatment
inferred← citeshttps://doi.org/10.1177/15353702231209413openalex-snapshot
Developing a SARS-CoV-2 main protease binding prediction random forest model for drug repurposing for COVID-19 treatment
inferred← citeshttps://doi.org/10.1186/s13578-022-00806-6openalex-snapshot
Ginkgolic acid and anacardic acid are reversible inhibitors of SARS-CoV-2 3-chymotrypsin-like protease
inferred← citeshttps://doi.org/10.1186/s44149-023-00075-xopenalex-snapshot
Roles of host proteases in the entry of SARS-CoV-2
inferred← citeshttps://doi.org/10.1248/cpb.c23-00562openalex-snapshot
Exploratory Studies of Effective Inhibitors against the SARS-CoV-2 Main Protease by Halogen Incorporation and Amide Bond Replacement
inferred← citeshttps://doi.org/10.14233/ajchem.2025.34335openalex-snapshot
Machine Learning Models for the Identification of SARS-CoV-2 Main Protease (Mpro) Inhibitors: Development and Validation of Three-dimensional (3D) Quantitative Structure-Activity Relationship (QSAR) and Pharmacophore Models
inferred← citeshttps://doi.org/10.18097/pbmc20226806444openalex-snapshot
The prediction of SARS-CoV-2 main protease inhibition with filtering by position of ligand
inferred← citeshttps://doi.org/10.26434/chemrxiv-2022-hmdd4openalex-snapshot
An Environmentally Responsible Synthesis of the SARS-CoV-2 Mpro Inhibitor Nirmatrelvir (PF‑07321332), the Active Ingredient in Paxlovid
inferred← citeshttps://doi.org/10.26434/chemrxiv-2023-v6j35openalex-snapshot
Native mass spectrometry reveals binding interactions of SARS-CoV-2 PLpro with inhibitors and ISG15
inferred← citeshttps://doi.org/10.3389/fmicb.2022.1031204openalex-snapshot
A reporter cell line for the automated quantification of SARS-CoV-2 infection in living cells
inferred← citeshttps://doi.org/10.3390/biom13091339openalex-snapshot
Recent Advances in SARS-CoV-2 Main Protease Inhibitors: From Nirmatrelvir to Future Perspectives
inferred← citeshttps://doi.org/10.3390/biom14070797openalex-snapshot
Inhibitors of SARS-CoV-2 Main Protease (Mpro) as Anti-Coronavirus Agents
inferred← citeshttps://doi.org/10.3390/covid3040034openalex-snapshot
Comparative Analysis and Classification of SARS-CoV-2 Spike Protein Structures in PDB
inferred← citeshttps://doi.org/10.3390/futurepharmacol3010006openalex-snapshot
SARS-CoV-2 Mpro Inhibitors: Achieved Diversity, Developing Resistance and Future Strategies
inferred← citeshttps://doi.org/10.3390/ijms26020670openalex-snapshot
Optimization of SARS-CoV-2 Mpro Inhibitors by a Structure-Based Multilevel Virtual Screening Method
inferred← citeshttps://doi.org/10.3390/ijms26052243openalex-snapshot
Identifying Exifone as a Dual-Target Agent Targeting Both SARS-CoV-2 3CL Protease and the ACE2/S-RBD Interaction Among Clinical Polyphenolic Compounds
inferred← citeshttps://doi.org/10.3390/life13020378openalex-snapshot
Investigation on the Essential Oils of the Achillea Species: From Chemical Analysis to the In Silico Uptake against SARS-CoV-2 Main Protease
inferred← citeshttps://doi.org/10.3390/molecules28145320openalex-snapshot
In Silico Discovery of Small-Molecule Inhibitors Targeting SARS-CoV-2 Main Protease
inferred← citeshttps://doi.org/10.3390/pathogens13100825openalex-snapshot
Advances in the Search for SARS-CoV-2 Mpro and PLpro Inhibitors
inferred← citeshttps://doi.org/10.4155/fmc-2023-0034openalex-snapshot
Structure-Based Discovery of Thiosemicarbazones As SARS-CoV-2 Main Protease Inhibitors
inferred← citeshttps://doi.org/10.4155/fmc-2024-0015openalex-snapshot
Design, synthesis and biological evaluation of novel 3C-like protease inhibitors as lead compounds against SARS-CoV-2
inferred← citeshttps://doi.org/10.5059/yukigoseikyokaishi.82.50openalex-snapshot
Chemistry of Covalent Drugs: Chemical Reactions with Endogenous Proteins in Live Cells
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.